This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Exelixis' Zanzalintinib and Adagene's Muzastotug in Metastatic Colorectal Cancer
Ticker(s): EXEL, ADAGWho's the expert?
Institution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 50+ patients a year with colorectal cancer
- Research interest in immune therapies for treating GI cancers
Interview GoalTo gain a deeper understanding of Exelixis' Zanzalintinib and Adagene's Muzastotug as potential treatments for metastatic colorectal cancer
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 13, 2026
- Call Time
- 11:00 AM EST
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
